

# Paul C Lorigan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6642459/publications.pdf>

Version: 2024-02-01

248  
papers

50,751  
citations

13827

67  
h-index

1456

220  
g-index

256  
all docs

256  
docs citations

256  
times ranked

41502  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2010, 363, 711-723.	13.9	13,065
2	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. <i>New England Journal of Medicine</i> , 2011, 364, 2507-2516.	13.9	6,976
3	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2521-2532.	13.9	4,838
4	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 375-384.	5.1	2,353
5	Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. <i>New England Journal of Medicine</i> , 2015, 372, 30-39.	13.9	2,240
6	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2012, 367, 107-114.	13.9	1,976
7	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	13.9	1,441
8	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet</i> , The, 2017, 390, 1853-1862.	6.3	1,032
9	Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology</i> , The, 2014, 15, 323-332.	5.1	890
10	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1239-1251.	5.1	812
11	Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 616-622.	0.8	720
12	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. <i>Lancet</i> , The, 2008, 372, 117-126.	6.3	620
13	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 226-235.	0.8	458
14	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3740-3748.	0.8	438
15	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigatorâ€™s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 383-390.	0.8	431
16	Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. <i>Lancet Oncology</i> , The, 2017, 18, 1116-1125.	5.1	415
17	Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 576-584.	0.8	403
18	Revised U.K. guidelines for the management of cutaneous melanoma 2010. <i>British Journal of Dermatology</i> , 2010, 163, 238-256.	1.4	343

#	ARTICLE	IF	CITATIONS
19	Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma. <i>Cancer Discovery</i> , 2013, 3, 158-167.	7.7	300
20	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. <i>JAMA Oncology</i> , 2020, 6, 519.	3.4	287
21	Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 4012-4019.	0.8	276
22	Chemotherapy Compared With Biochemotherapy for the Treatment of Metastatic Melanoma: A Meta-Analysis of 18 Trials Involving 2,621 Patients. <i>Journal of Clinical Oncology</i> , 2007, 25, 5426-5434.	0.8	255
23	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 449-58.	2.0	253
24	Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3144-3150.	0.8	238
25	Survival of patients with advanced metastatic melanoma: the impact of novel therapies—update 2017. <i>European Journal of Cancer</i> , 2017, 83, 247-257.	1.3	236
26	Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma. <i>Clinical Cancer Research</i> , 2010, 16, 1042-1048.	3.2	227
27	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	5.1	224
28	Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. <i>American Journal of Pathology</i> , 2009, 175, 808-816.	1.9	223
29	Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 53-61.	0.8	217
30	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. <i>Cancer Discovery</i> , 2016, 6, 286-299.	7.7	208
31	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3925-3936.	0.8	192
32	Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma. <i>Cancer Cell</i> , 2015, 27, 85-96.	7.7	188
33	Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naïve Patients With Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4787-4792.	0.8	176
34	Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). <i>Annals of Oncology</i> , 2013, 24, 2694-2698.	0.6	169
35	A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentialiation. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1191-1199.	1.1	164
36	Adjuvant interferon- $\gamma$ for the treatment of high-risk melanoma: An individual patient data meta-analysis. <i>European Journal of Cancer</i> , 2017, 82, 171-183.	1.3	159

#	ARTICLE	IF	CITATIONS
37	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. <i>Nature Medicine</i> , 2022, 28, 535-544.	15.2	158
38	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. <i>Lancet Oncology</i> , The, 2013, 14, 733-740.	5.1	151
39	Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. <i>Nature Cancer</i> , 2020, 1, 210-221.	5.7	138
40	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>European Journal of Cancer</i> , 2016, 53, 125-134.	1.3	137
41	Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2006, 95, 822-828.	2.9	135
42	Revised UK guidelines for the management of cutaneous melanoma 2010. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2010, 63, 1401-1419.	0.5	129
43	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. <i>Drugs</i> , 2016, 76, 925-945.	4.9	123
44	Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1582-1590.	0.3	122
45	Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2598-2603.	0.8	119
46	A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2011, 104, 750-755.	2.9	113
47	BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling. <i>Science Signaling</i> , 2014, 7, ra30.	1.6	113
48	Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 2551-2557.	0.8	108
49	A randomised, phase II study of intetumumab, an anti- $\alpha$ v-integrin mAb, alone and with dacarbazine in stage IV melanoma. <i>British Journal of Cancer</i> , 2011, 105, 346-352.	2.9	108
50	Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. <i>Nature Medicine</i> , 2015, 21, 741-750.	15.2	107
51	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 836-847.	5.1	104
52	Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. <i>Lancet Oncology</i> , The, 2005, 6, 773-779.	5.1	103
53	A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. <i>Supportive Care in Cancer</i> , 2008, 16, 201-208.	1.0	100
54	PD-L1 expression as a potential predictive biomarker. <i>Lancet Oncology</i> , The, 2015, 16, 1285-1287.	5.1	98

#	ARTICLE	IF	CITATIONS
55	Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. <i>Lancet Oncology</i> , 2014, 15, 620-630.	5.1	96
56	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 256-284.	1.3	92
57	The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. <i>Annals of Oncology</i> , 2010, 21, 2023-2028.	0.6	91
58	Randomized Phase III Trial Evaluating Spaltalizumab Plus Dabrafenib and Trametinib for BRAF <sup>V600E</sup> Mutant Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1428-1438.	0.8	90
59	Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 87-96.	3.0	89
60	A qualitative exploration of a respiratory distress symptom cluster in lung cancer: Cough, breathlessness and fatigue. <i>Lung Cancer</i> , 2011, 71, 94-102.	0.9	86
61	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF <sup>V600E</sup> -mutated melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 8502-8502.	0.8	86
62	Randomized Phase III Trial of Dose-Dense Chemotherapy Supported by Whole-Blood Hematopoietic Progenitors in Better-Prognosis Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2005, 97, 666-674.	3.0	85
63	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020, 130, 126-138.	1.3	84
64	The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit. <i>Annals of Oncology</i> , 2010, 21, 232-237.	0.6	80
65	The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. <i>Nature Communications</i> , 2021, 12, 4098.	5.8	80
66	Survival Benefits from Follow-Up of Patients with Lung Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1993-2004.	0.5	79
67	TNF- $\alpha$ increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes. <i>British Journal of Cancer</i> , 2003, 89, 1123-1129.	2.9	75
68	Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. <i>European Journal of Cancer</i> , 2018, 91, 116-124.	1.3	69
69	DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. <i>Annals of Oncology</i> , 2014, 25, 968-974.	0.6	68
70	Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , 1999, 35, 410-412.	1.3	67
71	Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. <i>Melanoma Research</i> , 2014, 24, 40-46.	0.6	67
72	Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization. <i>British Journal of Haematology</i> , 2002, 116, 291-298.	1.2	66

#	ARTICLE	IF	CITATIONS
73	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019, 116, 148-157.	1.3	64
74	Management of Small Cell Lung Cancer. <i>Drugs</i> , 2012, 72, 471-490.	4.9	63
75	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 119, 168-178.	1.3	61
76	Hyponatraemia secondary to nivolumab-induced primary adrenal failure. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, .	0.2	60
77	Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. <i>Clinical Lung Cancer</i> , 2017, 18, 68-76.e2.	1.1	59
78	A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). <i>Annals of Oncology</i> , 2006, 17, 1111-1119.	0.6	57
79	Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance. <i>Annals of Oncology</i> , 2015, 26, 33-39.	0.6	57
80	Monitoring tumour cells in the peripheral blood of small cell lung cancer patients. <i>Cytometry</i> , 2002, 50, 160-167.	1.8	56
81	Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis. <i>Lung Cancer</i> , 2011, 72, 378-383.	0.9	56
82	Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. <i>Health and Quality of Life Outcomes</i> , 2012, 10, 66.	1.0	55
83	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. <i>Lancet Oncology</i> , The, 2014, 15, 297-304.	5.1	55
84	Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 290-299.	1.2	55
85	Investigation of female survival benefit in metastatic melanoma. <i>British Journal of Cancer</i> , 1999, 80, 2025-2033.	2.9	53
86	Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 863-873.	2.0	53
87	Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma. <i>Annals of Oncology</i> , 2014, 25, 2052-2058.	0.6	53
88	Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma. <i>British Journal of Cancer</i> , 2001, 84, 499-503.	2.9	52
89	Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 582-590.	2.3	51
90	Gender and survival in malignant tumours. <i>Cancer Treatment Reviews</i> , 2001, 27, 201-209.	3.4	50

#	ARTICLE	IF	CITATIONS
91	Ipilimumab in the real world. <i>Melanoma Research</i> , 2015, 25, 432-442.	0.6	50
92	Characteristics of Women with Recurrent Molar Pregnancies. <i>Gynecologic Oncology</i> , 2000, 78, 288-292.	0.6	49
93	Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. <i>Cancer</i> , 2001, 92, 601-608.	2.0	49
94	Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. <i>Lung Cancer</i> , 2015, 88, 117-123.	0.9	49
95	Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. <i>British Journal of Cancer</i> , 2011, 105, 353-359.	2.9	48
96	No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients. <i>Molecular Oncology</i> , 2014, 8, 1140-1158.	2.1	47
97	Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. <i>Annals of Oncology</i> , 2018, 29, 1843-1852.	0.6	47
98	Systemic therapy for metastatic malignant melanoma – from deeply disappointing to bright future?. <i>Experimental Dermatology</i> , 2008, 17, 383-394.	1.4	46
99	Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. <i>British Journal of Cancer</i> , 2008, 99, 442-447.	2.9	43
100	Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence. <i>Journal of Clinical Oncology</i> , 2014, 32, 185-190.	0.8	43
101	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1068-1080.	0.8	43
102	Assessing the impact of diagnosis and the related supportive care needs in patients with cutaneous melanoma. <i>Supportive Care in Cancer</i> , 2015, 23, 779-789.	1.0	42
103	Considerations in Developing and Delivering a Nonpharmacological Intervention for Symptom Management in Lung Cancer: The Views of Patients and Informal Caregivers. <i>Journal of Pain and Symptom Management</i> , 2012, 44, 831-842.	0.6	41
104	Melanoma Cell Attachment, Invasion, and Integrin Expression is Upregulated by Tumor Necrosis Factor $\alpha$ and Suppressed by $\beta$ Melanocyte Stimulating Hormone. <i>Journal of Investigative Dermatology</i> , 2002, 119, 1165-1171.	0.3	40
105	High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. <i>British Journal of Cancer</i> , 2005, 93, 620-621.	2.9	40
106	O6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. <i>British Journal of Cancer</i> , 2009, 100, 1250-1256.	2.9	40
107	Radiotherapy for small-cell lung cancer – Where are we heading?. <i>Lung Cancer</i> , 2009, 63, 307-314.	0.9	40
108	The role of positron emission tomography in management of small cell lung cancer. <i>Lung Cancer</i> , 2011, 73, 121-126.	0.9	39

#	ARTICLE	IF	CITATIONS
109	Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study). <i>European Journal of Cancer</i> , 2012, 48, 2175-2182.	1.3	39
110	Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer – Evidence from a phase II trial. <i>Lung Cancer</i> , 2012, 76, 72-77.	0.9	39
111	A Phase 3 Randomized, Open-Label Study of Nivolumab (Anti-Pd-1; Bms-936558; Ono-4538) Versus Investigator'S Choice Chemotherapy (Icc) in Patients with Advanced Melanoma After Prior Anti-Ctla-4 Therapy. <i>Annals of Oncology</i> , 2014, 25, v1.	0.6	38
112	Modern Management of Small-Cell Lung Cancer. <i>Drugs</i> , 2007, 67, 2135-2152.	4.9	37
113	Protocol for the CONVERT trial—Concurrent ONce-daily VErus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. <i>BMI Open</i> . 2016. 6. e009849.	0.8	37
114	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	5.1	37
115	Management of small-cell lung cancer. <i>Annals of Oncology</i> , 2005, 16, ii235-ii239.	0.6	35
116	Improving Outcomes in Advanced Malignant Melanoma. <i>Drugs</i> , 2005, 65, 733-743.	4.9	35
117	Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. <i>European Journal of Cancer</i> , 2019, 116, 207-215.	1.3	35
118	Randomized Phase II Study of Two Gemcitabine Schedules for Patients With Impaired Performance Status (Karnofsky performance status $\geq$ 70) and Advanced Non–Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 2136-2144.	0.8	34
119	Discrepancies in Cancer Genomic Sequencing Highlight Opportunities for Driver Mutation Discovery. <i>Cancer Research</i> , 2014, 74, 6390-6396.	0.4	33
120	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. <i>European Journal of Cancer</i> , 2018, 91, 168-170.	1.3	33
121	Emergency presentations in patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020, 130, 193-197.	1.3	33
122	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 3741-3749.	0.8	33
123	Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. <i>Oncolmmunology</i> , 2018, 7, e1433516.	2.1	31
124	Lung cancer after treatment for breast cancer. <i>Lancet Oncology</i> , The, 2010, 11, 1184-1192.	5.1	30
125	Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer – EORTC 08062. <i>European Journal of Cancer</i> , 2011, 47, 2322-2330.	1.3	30
126	Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. <i>Nature Medicine</i> , 2022, 28, 752-765.	15.2	30



#	ARTICLE	IF	CITATIONS
127	Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient. <i>Melanoma Research</i> , 2009, 19, 333-334.	0.6	29
128	Fatal Pulmonary Fibrosis Associated with Induction Chemotherapy with Carboplatin and Vinorelbine Followed by CHART Radiotherapy for Locally Advanced Non-small Cell Lung Cancer. <i>Clinical Oncology</i> , 2002, 14, 361-366.	0.6	28
129	Sodium salicylate inhibits TNF- $\alpha$ -induced NF- $\kappa$ B activation, cell migration, invasion and ICAM-1 expression in human melanoma cells. <i>Melanoma Research</i> , 2006, 16, 11-22.	0.6	27
130	Biomarker analysis in a phase III study of pemetrexed+carboplatin versus etoposide+carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. <i>Annals of Oncology</i> , 2012, 23, 1723-1729.	0.6	27
131	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 121, 144-153.	1.3	27
132	Does Adjuvant Vaccine Therapy Really Have Activity in Malignant Melanoma?. <i>Journal of Clinical Oncology</i> , 2007, 25, 4693-4693.	0.8	26
133	The role for chemotherapy in the modern management of melanoma. <i>Melanoma Management</i> , 2017, 4, 125-136.	0.1	26
134	Applying Best-Worst scaling methodology to establish delivery preferences of a symptom supportive care intervention in patients with lung cancer. <i>Lung Cancer</i> , 2012, 77, 199-204.	0.9	25
135	Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. <i>Lung Cancer</i> , 2012, 78, 276-281.	0.9	25
136	Phase II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma. <i>British Journal of Cancer</i> , 2013, 109, 1451-1459.	2.9	25
137	Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. <i>Lung Cancer</i> , 2009, 64, 60-65.	0.9	24
138	Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1437-1448.	1.1	24
139	Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: A retrospective, longitudinal survey (MELODY study). <i>European Journal of Cancer</i> , 2012, 48, 3205-3214.	1.3	24
140	Enhanced Fatty Acid Scavenging and Glycerophospholipid Metabolism Accompany Melanocyte Neoplasia Progression in Zebrafish. <i>Cancer Research</i> , 2019, 79, 2136-2151.	0.4	24
141	Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer: Controversies and Future developments. <i>Clinical Oncology</i> , 2005, 17, 591-598.	0.6	23
142	Predicting the myelotoxicity of chemotherapy. <i>Melanoma Research</i> , 2011, 21, 502-508.	0.6	23
143	Systematic Review and Network Meta-Analysis of Overall Survival Comparing 3 mg/kg Ipilimumab With Alternative Therapies in the Management of Pretreated Patients With Unresectable Stage III or IV Melanoma. <i>Oncologist</i> , 2012, 17, 1376-1385.	1.9	23
144	Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma. <i>Nature Communications</i> , 2020, 11, 853.	5.8	23

#	ARTICLE	IF	CITATIONS
145	Thoracic Radiation Therapy for Limited-Stage Small-Cell Lung Cancer: Unanswered Questions. <i>Clinical Lung Cancer</i> , 2005, 7, 23-29.	1.1	22
146	Gestational choriocarcinoma of the ovary diagnosed by analysis of tumour DNA. <i>Cancer Letters</i> , 1996, 104, 27-30.	3.2	21
147	Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis. <i>British Journal of Cancer</i> , 1999, 81, 1037-1041.	2.9	21
148	Dabrafenib and its use in the treatment of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 199-208.	0.1	21
149	Considerations in developing and delivering a non-pharmacological intervention for symptom management in lung cancer: the views of health care professionals. <i>Supportive Care in Cancer</i> , 2012, 20, 2565-2574.	1.0	20
150	Adjuvant immunotherapy: the sting in the tail. <i>European Journal of Cancer</i> , 2020, 132, 207-210.	1.3	20
151	A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. <i>Cancer</i> , 2014, 120, 2016-2024.	2.0	19
152	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2021, 158, 156-168.	1.3	19
153	Oxidative stress from DGAT1 oncoprotein inhibition in melanoma suppresses tumor growth when ROS defenses are also breached. <i>Cell Reports</i> , 2022, 39, 110995.	2.9	19
154	Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells. <i>Oncotarget</i> , 2016, 7, 81995-82012.	0.8	18
155	Prognostic and predictive value of $\beta$ -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2022, 165, 97-112.	1.3	18
156	Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. <i>Lung Cancer</i> , 2011, 74, 75-9.	0.9	17
157	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172). <i>Journal of Clinical Oncology</i> , 2017, 35, 9524-9524.	0.8	17
158	Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e505-e514.	1.8	17
159	Novel Therapies for the Treatment of Small-Cell Lung Cancer. <i>Drugs</i> , 2006, 66, 1919-1931.	4.9	16
160	Current Drug Treatment Guidelines for Epithelial Ovarian Cancer. <i>Drugs</i> , 1996, 51, 571-584.	4.9	15
161	Small cell carcinoma of the cervix. <i>Clinical Oncology</i> , 1996, 8, 102-105.	0.6	13
162	Guidelines for the Stratification of Patients Recruited to Trials of Therapy for Low-Risk Gestational Trophoblastic Tumor. <i>Gynecologic Oncology</i> , 2000, 78, 92-96.	0.6	13

#	ARTICLE	IF	CITATIONS
163	An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>European Journal of Cancer</i> , 2019, 107, 175-185.	1.3	13
164	Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 1012-1015.	1.0	13
165	Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation. <i>European Journal of Cancer</i> , 1994, 30, 2085-2090.	1.3	12
166	Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate. <i>British Journal of Cancer</i> , 1997, 76, 1382-1386.	2.9	12
167	A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2005, 41, 1547-1550.	1.3	12
168	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	1.8	12
169	The role of nivolumab in melanoma. <i>Future Oncology</i> , 2018, 14, 1241-1252.	1.1	12
170	Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. <i>ESMO Open</i> , 2018, 3, e000317.	2.0	12
171	Cost-effectiveness of a policy-based intervention to reduce melanoma and other skin cancers associated with indoor tanning*. <i>British Journal of Dermatology</i> , 2022, 187, 105-114.	1.4	12
172	Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study. <i>British Journal of Dermatology</i> , 2014, 170, 87-95.	1.4	11
173	Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-223249.	0.2	11
174	25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. <i>British Journal of Cancer</i> , 2018, 119, 793-800.	2.9	11
175	Survival of patients with early invasive melanoma down-staged under the new eighth edition of the American Joint Committee on Cancer staging system. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 272-274.	0.6	11
176	Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop. <i>Annals of Oncology</i> , 2019, 30, 1038-1040.	0.6	11
177	Septicaemia and septic arthritis due to <i>Pseudomonas putida</i> in a neutropenic patient. <i>Journal of Infection</i> , 1991, 23, 346-347.	1.7	10
178	A Guideline for the Management of Gastrointestinal Stromal Tumour (GIST). <i>Sarcoma</i> , 2002, 6, 83-87.	0.7	10
179	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology</i> , The, 2015, 16, 15-17.	5.1	10
180	Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e505-e514.	1.8	10

#	ARTICLE	IF	CITATIONS
181	Circulating Tumour DNA in Melanoma – Clinic Ready?. Current Oncology Reports, 2022, 24, 363-373.	1.8	10
182	Oestrogenic Steroids and Melanoma Cell Interaction with Adjacent Skin Cells Influence Invasion of Melanoma Cells In Vitro. Pigment Cell & Melanoma Research, 2000, 13, 68-72.	4.0	9
183	Sequential Platinum-Based Chemotherapy-Thoracic Radiotherapy in Early Stage Non-Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 5051s-5056s.	3.2	9
184	Surrogate endpoints in advanced sarcoma trials: a meta-analysis. Oncotarget, 2018, 9, 34617-34627.	0.8	9
185	MDR-1 Expression in Non-Hodgkin's Lymphomas is Unrelated to Treatment Intensity or Response to Therapy. Leukemia and Lymphoma, 1995, 18, 297-302.	0.6	8
186	Improving Survival with Thoracic Radiotherapy in Patients with Small Cell Lung Cancer. The CONVERT and the REST Trials. Clinical Oncology, 2010, 22, 547-549.	0.6	8
187	The role of chemotherapy in the modern management of melanoma. Melanoma Management, 2014, 1, 173-184.	0.1	8
188	Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. International Journal of Cancer, 2021, 149, 1926-1934.	2.3	8
189	Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma. British Journal of Cancer, 2003, 88, 1335-1338.	2.9	7
190	A randomised trial evaluating Bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: An update. Ecancermedicalscience, 2009, 3, 108.	0.6	7
191	The place of PD-1 inhibitors in melanoma management. Lancet Oncology, The, 2015, 16, 873-874.	5.1	7
192	Sequential immunotherapy regimens – expect the unexpected. Lancet Oncology, The, 2016, 17, 854-855.	5.1	7
193	Sunbed Use among 11- to 17-Year-Olds and Estimated Number of Commercial Sunbeds in England with Implications for a “Buy-Back” Scheme. Children, 2021, 8, 393.	0.6	7
194	Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 651-660.	1.8	7
195	Identifying melanomas in primary care: can we do better?. BMJ, The, 2012, 345, e4244-e4244.	3.0	6
196	Advances in the treatment of late stage melanoma. BMJ, The, 2013, 346, f1265-f1265.	3.0	6
197	DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244); Tj ETQq1 1 0.784314 rgBT /Ove 0.8 6	0.8	6
198	Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial.. Journal of Clinical Oncology, 2017, 35, 9501-9501.	0.8	6

#	ARTICLE	IF	CITATIONS
199	Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue. <i>British Journal of Haematology</i> , 2007, 137, 436-442.	1.2	5
200	Does adjuvant ipilimumab have little adverse effect on quality of life?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 395-396.	12.5	5
201	Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 651-660.	1.8	5
202	Patient engagement in melanoma research: from bench to bedside. <i>Future Oncology</i> , 2021, 17, 3705-3716.	1.1	5
203	Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA9000-LBA9000.	0.8	5
204	T cell immune awakening in response to immunotherapy is age-dependent. <i>European Journal of Cancer</i> , 2022, 162, 11-21.	1.3	5
205	Reasons for using indoor tanning devices: A systematic review of qualitative evidence. <i>British Journal of Health Psychology</i> , 2023, 28, 22-46.	1.9	5
206	Radiotherapy in Extensive-disease Small Cell Lung Cancer. A Survey of Current UK Practice. <i>Clinical Oncology</i> , 2009, 21, 78.	0.6	4
207	Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. <i>Manchester lung cancer group. Lung Cancer</i> , 2011, 73, 338-344.	0.9	4
208	Emergency management of immune-related hypophysitis: Collaboration between specialists is essential to achieve optimal outcomes. <i>Cancer</i> , 2018, 124, 4731-4731.	2.0	4
209	Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities. <i>European Journal of Cancer</i> , 2022, 164, 62-69.	1.3	4
210	Melanoma vaccines "they should work. <i>Annals of Oncology</i> , 2006, 17, 539-541.	0.6	3
211	Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 635-640.	1.1	3
212	Update on targeted therapies for small cell carcinoma of the lung. <i>Targeted Oncology</i> , 2008, 3, 205-215.	1.7	3
213	Extensive-stage small-cell lung cancer"moving beyond response rate?. <i>Annals of Oncology</i> , 2009, 20, 801-802.	0.6	3
214	Integrating radiation therapy with emerging systemic therapies: Lessons from a patient with cerebral radionecrosis, spinal cord myelopathy, and radiation pneumonitis. <i>Practical Radiation Oncology</i> , 2016, 6, 110-113.	1.1	3
215	Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma. <i>ESMO Open</i> , 2020, 5, e000707.	2.0	3
216	Lenvatinib combined with dacarbazine versus dacarbazine alone as first-line treatment in patients with stage IV melanoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9027-9027.	0.8	3

#	ARTICLE	IF	CITATIONS
217	Continuous infusion of 5-fluorouracil with alpha 2b interferon for advanced colorectal carcinoma. British Journal of Cancer, 1995, 72, 193-197.	2.9	2
218	Palliative treatment. Hematology/Oncology Clinics of North America, 2004, 18, 417-432.	0.9	2
219	510 POSTER Phase I study of IMGN901 (BB-10901) in patients with CD56-positive solid tumours. European Journal of Cancer, Supplement, 2008, 6, 162.	2.2	2
220	Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008. Pigment Cell and Melanoma Research, 2009, 22, 532-543.	1.5	2
221	Urgent treatment of patients with metastatic melanoma using braf inhibitors in the absence of braf mutation status. Annals of Oncology, 2013, 24, 1712-1713.	0.6	2
222	Vemurafenib-induced nonautoimmune haemolytic anaemia. Melanoma Research, 2014, 24, 418-419.	0.6	2
223	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply. Lancet Oncology, The, 2021, 22, e343-e344.	5.1	2
224	Monitoring neutrophil phagocytosis in lung cancer patients or normal stem cell donors, treated with G-CSF. Biochemical Society Transactions, 1997, 25, 197S-197S.	1.6	1
225	O-153 Phase III randomised trial of doxorubicin based chemotherapy compared with platinum based chemotherapy in both limited and extensive stage patients. Lung Cancer, 2005, 49, S52-S53.	0.9	1
226	Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer. Lung Cancer, 2006, 53, 165-170.	0.9	1
227	A Review of the Treatment Strategies for Small Cell Lung Carcinoma Patients with a Poor Performance Status. Current Respiratory Medicine Reviews, 2006, 2, 59-66.	0.1	1
228	Prophylactic cranial irradiation (PCI) in extensive disease (ED) small cell lung cancer (SCLC): an audit of practice. Lung Cancer, 2008, 60, S4.	0.9	1
229	High-risk cutaneous melanoma follow-up: time for more intensive surveillance?. Melanoma Management, 2014, 1, 7-10.	0.1	1
230	Reply to – Comment on – Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy – British Journal of Cancer, 2017, 116, e15-e15.	2.9	1
231	Reply to E. Hindi – Journal of Clinical Oncology, 2021, 39, 944-946.	0.8	1
232	Abstract 3704: Novel panRAF inhibitors active in melanomas that are resistant to BRAF-selective, or BRAF-selective/MEK inhibitor combinations. , 2014, , .		1
233	Abstract CT331: Phase I/II trial of a novel antibody DNA immunotherapy, targeting CD64, in the treatment of Melanoma. , 2014, , .		1
234	A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.. Journal of Clinical Oncology, 2012, 30, TPS8605-TPS8605.	0.8	1

#	ARTICLE	IF	CITATIONS
235	O-095 A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small cell lung cancer â€” A randomised multicentre trial of the British thoracic oncology group (BTOG1). Lung Cancer, 2005, 49, S34.	0.9	0
236	Platinum-based chemotherapy with thoracic radiotherapy in stage III good performance status non-small cell lung cancer patients. European Journal of Cancer, Supplement, 2005, 3, 41-50.	2.2	0
237	Re: Small Cell Lung Cancer Treated in Southeast Wales, Lester etÂal., Clin Oncol 2006;18:378â€”382. Clinical Oncology, 2006, 18, 722-723.	0.6	0
238	35 CONVERT-A multicentre randomised controlled NCRN trial comparing accelerated twice-daily and high dose once-daily thoracic radiotherapy in good performance status (PS), limited small-cell lung cancer (LD SCLC) treated concurrently with cisplatin and etoposide. Lung Cancer, 2007, 57, S10.	0.9	0
239	Small Cell Lung Cancer (SCLC); any progress?. European Journal of Cancer, Supplement, 2007, 5, 398-399.	2.2	0
240	Tarceva in relapsed non-small cell lung cancer: experience from Northwest England. Lung Cancer, 2008, 60, S25-S26.	0.9	0
241	Targeting angiogenesis in melanoma. Expert Review of Dermatology, 2009, 4, 237-248.	0.3	0
242	Efficacy of Positron Emission Tomography Staging for Small-Cell Lung Cancer: A Systematic Review and Cost Analysis in the Australian Setting. Journal of Thoracic Oncology, 2012, 7, e25.	0.5	0
243	Authors' reply to Bayley and Cave. BMJ, The, 2012, 345, e5417-e5417.	3.0	0
244	Nivolumab in treating advanced melanoma. British Journal of Health Care Management, 2016, 22, 294-296.	0.1	0
245	Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). Annals of Translational Medicine, 2017, 5, 390-390.	0.7	0
246	Anti-Angiogenesis Therapy for Melanoma. , 2012, , 281-294.		0
247	AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence.. Journal of Clinical Oncology, 2013, 31, LBA9000-LBA9000.	0.8	0
248	Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma. British Journal of Cancer, 2022, 126, 1450-1456.	2.9	0